ERBB2 and invasive ductal breast carcinoma: A similar observation was reported in a recent French study, which found that only HER2‐positive invasive ductal carcinomas responded to targeted anti‐HER2 therapy, and this effect was not seen in HER2‐positive lobular carcinoma [3].